METAVAX® our proprietary innovative vaccine platform

Our platform is built on the WHO recommended production host *Hansenula polymorpha* and our unique duck hepatitis B virus like particle (dHBs).

www.artes-biotechnology.com
**METAVAX®**

Competitive advantages are:
- no virus clearance
- no endotoxins
- no cross-reactivity

VLP’s for presentation of:
- very large (600 aa) antigens
- multimeric antigens
- multiple antigens on 1 VLP
- conformational epitopes
- membrane proteins

**ARTES offers** the proprietary **METAVAX®** platform for stable, cost efficient and fast vaccine development and manufacturing.

ARTES’ offer includes the delivery of:
- cell lines
- production processes
- analytics
- preclinical material
- GMP batches
- process transfer

Validated for:
- **Malaria**..............a.o. CSP, AMA1& MSP2
- **Flu**......................a.o. H5N1 hemagglutinin
- **Hepatitis C**.........E1/E2
- **HIV**.....................gp140

- self-adjuvanting vaccines
- B and T-cell specific immune response

**ARTES Biotechnology GmbH**
Elisabeth-Selbert-Str. 9, 40764 Langenfeld, Germany, +49 (0) 2173 27587 0
www.artes-biotechnology.com, info@artes-biotechnology.com